Katia Cannita - Concepedia

Author

Katia Cannita

University of L'Aquila ORCID

Also Known As

Cannita Katia, Giorgio Bosso, K Cannita, K. Cannita, K., Cannita, KATIA CANNITA, Katia CANNITA, Katia Cannita

300

Publications

Citations

H-Index

Concepts

All Affiliations

University of L'Aquila San Salvatore Hospital University of Chieti-Pescara Sapienza University of Rome Ospedale Santa Maria Goretti

About

Katia Cannita is an author at University of L'Aquila specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	1.1K
2	Health Sciences	7	7	561
3	Nursing	2	2	154
4	Biostatistics	2	2	31
5	Social Sciences	1	1	20

Katia Cannita

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Journal for ImmunoTherapy of Cancer	2019	400
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Alessio Cortellini, Sebastiano Buti, Daniele Santini, The Oncologist ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy	2019	214
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Journal for ImmunoTherapy of Cancer	2021	132
Physical Exercise and Quality of Life in Breast Cancer Survivors Marco Valenti, Giampiero Porzio, Federica Aielli, International Journal of Medical Sciences Quality Of LifePhysical ActivityPhysical Activity ProgramsCancer ManagementExercise Oncology	2008	124
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events Alessio Cortellini, Melissa Bersanelli, Daniele Santini, European Journal of Cancer Cancer ImmunosurveillanceMedicineBody Mass IndexImmunologyImmunoediting	2020	120
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study Alessio Cortellini, Federico Bozzetti, Pierpaolo Palumbo, Scientific Reports	2020	87
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Clinical Lung Cancer Pd-l1 ExpressionClinical EpidemiologyImmunologyImmune Checkpoint InhibitorClinical Outcomes	2020	82
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity G. Cianci, Micaela Morelli, Katia Cannita, British Journal of Cancer	2003	71
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience Patrizia Vici, Laura Pizzuti, Andrea Michelotti, Oncotarget	2017	68

Page 1